Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
Status:
Completed
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study
in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of ITI-214.